Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D. Shaaltiel Y, et al. Among authors: hashmueli s. Plant Biotechnol J. 2007 Sep;5(5):579-90. doi: 10.1111/j.1467-7652.2007.00263.x. Epub 2007 May 24. Plant Biotechnol J. 2007. PMID: 17524049 Free article.
Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Muñoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D. Zimran A, et al. Among authors: hashmueli s. Blood. 2011 Nov 24;118(22):5767-73. doi: 10.1182/blood-2011-07-366955. Epub 2011 Sep 6. Blood. 2011. PMID: 21900191 Free article. Clinical Trial.
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, Hakim M, Hashmueli S, Friedman I, Sapir Y, Greco R, Qu H, Nestle F, Wiederschain D, Pao L, Sharma S, Ben Moshe T. Mandel I, et al. Among authors: hashmueli s. J Immunother Cancer. 2022 Sep;10(9):e004859. doi: 10.1136/jitc-2022-004859. J Immunother Cancer. 2022. PMID: 36096532 Free PMC article.
ICSBP/IRF-8 transactivation: a tale of protein-protein interaction.
Levi BZ, Hashmueli S, Gleit-Kielmanowicz M, Azriel A, Meraro D. Levi BZ, et al. Among authors: hashmueli s. J Interferon Cytokine Res. 2002 Jan;22(1):153-60. doi: 10.1089/107999002753452764. J Interferon Cytokine Res. 2002. PMID: 11846986 Review.
Interaction between interferon consensus sequence-binding protein and COP9/signalosome subunit CSN2 (Trip15). A possible link between interferon regulatory factor signaling and the COP9/signalosome.
Cohen H, Azriel A, Cohen T, Meraro D, Hashmueli S, Bech-Otschir D, Kraft R, Dubiel W, Levi BZ. Cohen H, et al. Among authors: hashmueli s. J Biol Chem. 2000 Dec 15;275(50):39081-9. doi: 10.1074/jbc.M004900200. J Biol Chem. 2000. PMID: 10991940 Free article.
11 results